

latanoprost, timolol eyedrops (Xalacom[®])

(No. 432/07)

Pfizer Ltd

Product Update

7 December 2007

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

latanoprost, timolol (Xalacom[®]) is accepted for use within NHS Scotland for reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

This abbreviated submission relates to a licence extension to cover use of this medicine in patients insufficiently responsive to a prostaglandin analogue used alone. Xalacom[®] is suitable for patients in whom timolol and latanoprost are appropriate choices of beta-blocker and prostaglandin analogue respectively. It costs less than the individual preparations.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 October 2007.

**Chairman,
Scottish Medicines Consortium**